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Summary
The exquisite control of growth factor function by heparan sulfate (HS) is dictated by the
tremendous structural heterogeneity of sulfated modifications. It is not known how specific HS
structures control growth factor-dependent progenitor expansion during organogenesis. We
isolated KIT+ progenitors from fetal salivary glands during a stage of rapid progenitor expansion
and profiled HS biosynthetic enzyme expression. Enzymes generating a specific type of 3-O-
sulfated-HS (3-O-HS) are enriched, and FGF10/FGFR2b signaling directly regulates their
expression. Bioengineered 3-O-HS binds FGFR2b and stabilizes FGF10/FGFR2b complexes in a
receptor- and growth factor-specific manner. Rapid autocrine feedback increases 3-O-HS, KIT and
progenitor expansion. Knockdown of multiple Hs3st isoforms limits fetal progenitor expansion,
but is rescued with bioengineered 3-O-HS, which also increases adult progenitor expansion.
Rapidly altering a specific 3-O-sulfated epitope provides a cellular mechanism to modulate the
response to FGFR2b signaling and control progenitor expansion. 3-O-HS may expand KIT+
progenitors in vitro for regenerative therapy.
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During organogenesis, fibroblast growth factor receptor 2b (FGFR2b) signaling is essential
for progenitor survival and proliferation in the submandibular gland (SMG), lung, pancreas,
tooth and skin (De Moerlooze et al., 2000; Petiot et al., 2003). It is well established that
heparan sulfate proteoglycans are coreceptors for FGFR2b (Mohammadi et al., 2005) and
specific HS structures are critical for FGFR2b-dependent proliferation (reviewed in Patel
and Hoffman, 2013; Patel et al., 2006). The genetic deletion of HS biosynthetic enzymes
highlights that HS is essential for organogenesis (Bishop et al., 2007). Due to the
tremendous variation in sulfate modifications of HS, the sulfotransferase enzymes provide
an attractive mechanism to increase the cellular specificity to HS-binding growth factors and
to fine-tune the biological responses to FGFR2b signaling.
The HS 3-O-sulfotransferase (Hs3st) family is the largest family of sulfotransferase enzymes
with seven isoforms in mice and humans. However, 3-O-sulfation is the least abundant
sulfate modification and occurs at the terminal step of HS biosynthesis within the Golgi.
Although all seven isoforms add a 3-O-sulfate, they generate two types of modifications
(Lawrence et al., 2007; Xu et al., 2008). The first, termed Hs3st1-like activity, occurs when
Hs3st1 adds a sulfate to a glucosamine adjacent to either a glucuronic or an iduronic acid in
the HS chain. This well-studied type of 3-O-sulfated modification occurs in the antithrombin
(AT) binding pentasaccharide (Lindahl et al., 1980). The second, termed Hs3st3-like
activity, occurs when Hs3st isoforms -2, -3a1, -3b1, -4, or -6 add a 3-O-sulfate to a
glucosamine adjacent to a 2-O-sulfated iduronic acid. For example, this forms a cell surface
HS epitope that allows herpes simplex virus (HSV-1) entry (Shukla et al., 1999). Lastly,
Hs3st5 can generate both types of modifications (Liu and Pedersen, 2007).
Only two of the Hs3st’s have been genetically deleted in mice. Loss of Hs3st1 results in
postnatal lethality with intrauterine growth retardation (HajMohammadi et al., 2003) and
mice deficient in Hs3st2 are viable (Hasegawa and Wang, 2008). Hs3st’s have distinct roles
in other organisms. For instance, a reduction of Hs3st-B affects D. melanogaster
neurogenesis (Kamimura et al., 2004), hst-3.1 and hst-3.2 mediate neurite branching in C.
elegans, (Tecle et al., 2013), while in D. rerio Hs3st5 controls cilia length, Hs3st6 regulates
cell motility (Neugebauer et al., 2013) and Hs3st7 regulates cardiac contraction (Samson et
al., 2013). However, the specific roles of the Hs3st3 isoforms during mammalian
development are unknown.
Recently, we reported that the highly proliferative distal endbuds of SMGs and lungs
contain progenitors expressing the KIT receptor and FGFR2b, and that combined KIT/
FGFR2b signaling is critical for their maintenance and expansion (Lombaert et al., 2013).
Here we discover that KIT+ epithelial progenitors preferentially synthesize Hs3st3-modified
HS to rapidly increase FGFR2b-mediated signaling and proliferation. 3-O-HS-dependent
signaling results in autocrine feedback to upregulate Hs3st3 and Kit expression. We propose
that 3-O-HS controls the FGFR2b-dependent expansion of KIT+ progenitors during
organogenesis and during the in vitro expansion of adult progenitors.
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KIT+ epithelial cells are enriched in Hs3st3a1 and Hs3st3b1 transcripts and 3-O-sulfated
HS is localized in KIT+ epithelial endbuds
Since HS is required for high-affinity binding of FGF10 to FGFR2b, we hypothesized that a
progenitor-specific HS modification on proteoglycans controlled FGFR2b-dependent
proliferation. We first screened the HS biosynthetic enzyme expression in SMG epithelium
and mesenchyme at embryonic day (E) 13, to identify which enzymes were expressed in the
epithelium (Figure 1A). Transcripts for Hs3st1, Hs3st3a1, Hs3st3b1 and Hs3st6 were
predominantly in epithelia, whereas Hs3st2, Hs3st4 and Hs3st5 were in the mesenchyme.
Other HS biosynthetic enzymes such as Hs2st1, Hs6st1 and Ndst1 were equally expressed in
both compartments. Cdh1 and Fgf10 served as controls for the separation of the epithelium
and mesenchyme, respectively. We then used KIT and E-cadherin (ECAD) antibodies to
FACS sort the epithelial KIT+ progenitors, which are mainly localized in the endbuds in
E13 SMGS (Figure 1B). We profiled the expression of HS biosynthetic enzymes in the KIT
+ECAD+ and KIT−ECAD+ cell populations using qPCR. Interestingly, the FACS sorted
KIT+ cells showed increased expression of specific HS-3-O-sulfotransferase isoforms,
Hs3st3a1 and Hs3st3b1, compared to KIT− cells. We confirmed that KIT+ cells are
enriched for genes associated with proliferation and FGFR signaling by the increase in
Ccnd1, Fgfr1b, and the downstream targets of FGFR signaling Etv4, Etv5, and Myc (Figure
1B). We screened HS proteoglycan core proteins in the KIT+ cells, although some were
enriched, none were significantly increased in expression (Figure S1A). These data indicate
that the highly proliferating KIT+ECAD+ progenitors express a unique set of
sulfotransferase enzymes.
Whole-mount in situ analysis of E13 SMGs confirmed the localization of Hs3st1, Hs3st3a1
and Hs3st3b1 in epithelial endbuds, and Hs6st1 in both the epithelium and mesenchyme
(Figure 1C and S1B). Hs3st6 was barely detectable by qPCR and we were unable to detect it
by in situ analysis (data not shown). We also analyzed the temporal expression of the Hs3st
enzymes throughout SMG development by qPCR (Figure S1C). Hs3st1, Hs3st3a1 and
Hs3st3b1 were more abundant early in SMG development when KIT+ progenitors
proliferate to increase organ size. By comparing the expression with other fetal organs at
E12, including the heart, kidney, liver, limb, lung and brain (Figure S1D), distinct tissue-
specific expression patterns of 3-O-sulfotransferases were apparent. For example, Hs3st4
and Hs3st5 were highly expressed in the brain, whereas Hs3st6 was high in the kidney
(Figure S1D).
Next, it was important to confirm that 3-O-HS was present on SMG epithelial cells (Figure
1D and E). We incubated SMGs with fluorescent Alexa 488-labeled antithrombin (AT488),
which recognizes the 3-O-HS pentasaccharide epitope generated by the Hs3st1 enzyme
(Girardin et al., 2005). We also incubated SMGs with a truncated ectodomain of HSV-1gD,
which binds to the Hs3st3-modified HS (Krummenacher et al., 1999; Shukla et al., 1999).
Both AT488 and HSV-1gD specifically labeled HS on the SMG epithelial cell surface.
Pretreatment with heparitinase III (HPT) specifically abolished labeling, whereas
chondroitinase ABC (CHABC), which removes chondroitin sulfates, did not (Figure 1D and
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E). In addition, incubation with excess AT-binding pentasaccharide or unlabeled AT
competed the AT488 binding (not shown). Taken together, we show that Hs3st enzymes are
specifically localized to epithelial endbuds that contain the KIT+ progenitors, and that 3-O-
HS is present on their cell surface.
Hs3st3 expression is directly regulated by FGFR2b signaling
We then investigated whether either FGF10/FGFR2b or KIT signaling directly regulates the
expression of Hs3st isoforms. Isolated epithelia were treated with FGF10 for 1, 2, and 4
hours (hr), and Hs3st isoform expression was measured by qPCR. No morphological
differences in the treated epithelium were observed at these short time points (Figure 2A).
Surprisingly, Hs3st3a1 and Hs3st3b1 expression increased by 2 hr and by 4 hr Hs3st3a1
expression increased 7-fold. By 4 hr, the expression of Hs3st1 and Hs3st6 had also
increased. As expected, Myc, an early response gene of FGF10/FGFR2b signaling, increased
within 1 hr while the expression of Ndst1, Hs2st1 and Hs6st1 did not change during this
time (Figure 2A). We also confirmed that the expression of Kitl increased at 4 hr whereas
Kit did not, as previously shown (Lombaert et al., 2013). Importantly, the increase in 3-O-
sulfotransferase genes occurred more rapidly than Etv5, a known downstream target of
FGF10/FGFR2b signaling.
To identify the downstream signaling pathway regulating Hs3st expression, isolated
epithelia were treated for 4 hr with FGF10 and either an FGFR inhibitor (SU5402),
recombinant FGFR2b, a MAPK inhibitor (UO126), a PI3-K inhibitor (LY294002) or a KIT
inhibitor (ISCK) (Figure 2B). As predicted, no morphological differences were observed,
but there was reduced expression of Hs3st3a1 and Hs3st3b1 in epithelia treated with the
FGFR inhibitor, recombinant FGFR2b, and MAPK inhibitor, but not with the PI3-K or KIT
inhibitors (Figure 2B). There was also reduced expression of Etv4, Etv5, Ccnd1, Myc, Kit
and Kitl with recombinant FGFR2b and MAPK inhibitors, and reduced expression of Etv4
with the PI3-K and FGFR inhibitors. The specific KIT inhibitor did not affect the expression
of any genes except for Kitl at 4 hr.
Although KIT signaling did not directly regulate Hs3st3 expression, we previously reported
that a reduction in KIT signaling in vivo diminishes organ growth by depleting KIT+
progenitors (Lombaert et al., 2013). Therefore, we analyzed the expression of Hs3st3a1 and
Hs3st3b1 in E13 SMGs from KitW/W mice, which have a mutation in KIT that inhibits
signaling, as well as SMGs treated with the KIT inhibitor for 24 hr. In both situations, there
was a decrease in branching morphogenesis (Figure 2C) and reduced expression of
Hs3st3a1 and Hs3st3b1 (Figure 2D). Interestingly, Hs3st6 expression increased in KitW/W
SMGs compared to the wild-type glands, suggesting that in vivo compensation with other
Hs3st isoforms may occur. Overall, these data suggest that an FGF10/FGFR2b-mediated
MAPK pathway rapidly and directly regulates Hs3st3 expression, and that the reduced
proliferation by loss of KIT signaling correlates with reduced levels of Hs3st3s.
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3-O-sulfated-HS binds FGFR2b to enhance 3-O-HS/FGF10/FGFR2b ternary complex
formation and proliferation
In order to investigate the molecular mechanism of how 3-O-HS could rapidly control
progenitor expansion, we bioengineered HS with 3-O-sulfated epitopes generated by
different Hs3st enzymes. We used HS isolated from bovine kidney, because it has low levels
of endogenous 3-O-sulfation (Xu et al., 2008). This kidney HS (simply termed HS here) was
treated with recombinant Hs3st1 and Hs3st3 enzymes to generate two types of 3-O-HS,
denoted as 3st1-HS and 3st3-HS, respectively (Figure S2A). The enzymatic treatment was
monitored by radioactive sulfate incorporation and only one or two 3-O-sulfates were added
per 14 kDa HS chain, which had on average 48 sulfates/chain, thereby increasing overall
sulfation by only 2–4% (see Experimental procedures and (Xu et al., 2008)). The current
model of an HS/FGF10/FGFR2b ternary signaling complex predicts that HS could function
to promote FGFR2b dimerization, stabilize the interactions of FGF10 with the receptor
and/or stabilize direct receptor-receptor contacts (Mohammadi et al., 2005). We used a
variety of biochemical assays to define how 3-O-HS functions.
To determine whether 3-O-HS could bind to either FGFR2b or FGF10, a solid-phase HS-
binding assay was used. The 3-O-HS was immobilized in GAG-binding plates and
recombinant FGFR2b-Fc or FGF10 were added. Binding was measured with an anti-Fc
antibody to detect FGFR2b or an anti-FGF10 antibody. Heparin, which binds both FGFR2b
and FGF10 and is highly sulfated (including 3-O-sulfation), was used as a positive control
and chondroitin sulfate A as a negative control. We observed increased FGFR2b binding to
3st3-HS compared to 3st1-HS or HS (Figure 3A). As expected, recombinant FGFR1b did
not bind to HS (Figure 3A). FGF10 also did not bind to the immobilized 3-O-HS any more
than chondroitin sulfate (Figure 3B), even at concentrations 10-fold higher than that used for
FGFR2b binding. Heparin decasaccharides (2,6S-Hep) that increase FGF10 bioactivity
(Patel et al., 2008) were used as a positive control for FGF10 binding and bound more
FGF10 than FGFR2b (Figure 3B). These data suggest that 3-O-HS preferentially interacts
with FGFR2b and not FGF10.
To determine whether 3-O-HS stabilizes FGF10/FGFR2b complex formation, equimolar
amounts of recombinant FGFR2b, FGF10 and HS were mixed, and then FGFR2b was
immunoprecipitated and blotted for both FGFR2b and FGF10. As expected, HS increased
the ternary complex formation and more FGF10 was detected, compared to when HS was
not added. However, the addition of either 3st1-HS or 3st3-HS further increased the amount
of FGF10 pulled down in the complex (Figure 3C). This shows that 3-O-HS enhances the
ternary 3-O-HS/FGF10/FGFR2b signaling complex formation by binding to FGFR2b,
which may affect downstream outcomes.
To determine whether 3-O-HS specifically enhances FGFR2b-dependent proliferation, we
used BaF3 cell assays. These cells do not express endogenous HS or FGFRs, and they do
not proliferate in response to FGF or heparin alone (Zhang et al., 2006). Proliferation of
FGFR2b- and FGFR1b-expressing BaF3 cells was compared following incubation with
either FGF10 or FGF1 and 3-O-HS, using heparin and chondroitin sulfate as positive and
negative controls, respectively. With FGF10 treatment, both 3st1-HS and 3st3-HS increased
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FGFR2b-BaF3 but not FGFR1b-BaF3 cell proliferation compared to HS, with 3st3-HS
having the greatest increase (70% of heparin) (Figure 3D). With FGF1 treatment, the
proliferation of FGFR1b-BaF3, FGFR2b-BaF3 and FGFR3c-BaF3 cells was similar with
either 3-O-HS or HS (Figure 3D and Figure S2), suggesting the response to 3-O-HS is both
receptor- and growth factor-dependent.
3-O-HS/FGF10/FGFR2b increases SMG epithelial cell proliferation and regulates FGFR2b-
dependent gene expression
To confirm that 3-O-HS also elicits an FGF10-dependent mitotic response in SMG
epithelium, we measured changes in epithelial morphogenesis and proliferation after the
addition of either 3st1-HS or 3st3-HS compared to HS. The addition of 3st3-HS increased
epithelial morphogenesis more than 3st1-HS (Figure 4A). Morphogenesis was expressed as
a morphogenic index (endbud number × width × duct length, in AU) (Figure 4A). The
addition of 3st3-HS also had a greater effect (2-fold compared to HS) than 3st1-HS on
proliferation, which was quantified using EdU (5’-ethynyl-2’-deoxyuridine) labeling (Figure
4B). To confirm that this proliferation was MAPK-dependent (as suggested in Figure 2), we
measured p42/44MAPK downstream of 3-O-HS after 1 hr and 24 hr. Both 3-O-HS increased
p42/44MAPK compared to HS within 1 hr, and this was maintained at 24 hr. Again, the
increase with 3st3-HS was greater than with 3st1-HS (Figure 4C).
We then measured gene expression downstream of 3-O-HS treatment. Both 3st1-HS and
3st3-HS specifically increased Hs3st1, Hs3st3a1 and Hs3st3b1, but not the other HS
sulfotransferases (Figure 4D), suggesting that positive autocrine feedback increased 3-O-HS.
In addition, 3-O-HS increased the expression of genes downstream of FGFR2b signaling
Etv4, Etv5, Myc, and Ccnd1, and Kit and Kitl. Although 3st1-HS and 3st3-HS affected
similar genes, 3st3-HS had a greater effect on expression. To confirm that this occurs in
other systems, we treated E11 lung endbuds with FGF10 and 3-O-HS or HS (Figure S3).
Similar to SMGs, the 3st3-HS increased both morphogenesis and the expression of
FGFR2b-dependent transcription factors involved in lung endbud progenitor development,
Etv5, Sox9 and Id2 (Lombaert et al., 2013; Rock and Hogan, 2011). Taken together, these
data suggest that 3-O-HS increases and maintains FGFR2b-dependent signaling and
proliferation of endbud progenitors.
Knockdown of Hs3sts reduces FGF10/FGFR2b-dependent growth and both are rescued
with exogenous 3-O-HS
Next, we predicted that reducing Hs3st gene expression by RNAi would reduce FGFR2b-
dependent epithelial proliferation. We used at least two different siRNAs for each isoform
but the knockdown of individual Hs3st3 isoforms or Hs3st1 did not affect morphogenesis
(Data not shown). Therefore, we designed an siRNA that targeted common regions of the
Hs3st3a1, Hs3st3b1 and Hs3st6 isoforms and pooled it with one targeting Hs3st1. Together
they reduced epithelial morphogenesis and Hs3st expression (Figure 5A and 5B). The
siRNAs reduced Hs3st1, Hs3st3a1, Hs3st3b1 and Hs3st6 but not the other HS
sulfotransferases such as Ndst1, Hs2st1 or Hs6st1 (Figure 5C). Hs3st knockdown also
reduced expression of the Etv4, Etv5, Ccnd1, Kit and Kitl (Figure 5C), consistent with 3-O-
HS being involved in FGF10/FGFR2b signaling and proliferation of KIT+ progenitors. We
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predicted that exogenous 3-O-HS would rescue the effects of knocking down Hs3st
expression and increase FGFR2b-dependent proliferation. We added HS to control siRNA-
treated epithelium at a dose that did not increase proliferation (Figure 5D and E). However,
similar concentrations of both 3st1-HS and 3st3-HS rescued morphogenesis in Hs3st-siRNA
treated epithelium compared to HS alone. Despite similar concentrations, 3st3-HS had
greater effects (Figure 5D and 5E) and also overcame the effects of siRNA and increased the
expression of Hs3st1, Hs3st3a1 and Hs3st3b1 (Figure 5F). Together, these data show that 3-
O sulfated HS controls FGF10/FGFR2b-dependent proliferation, and that exogenous 3-O-
HS increases Hs3st gene expression to overcome the effects of the siRNA in culture.
Overall, our data suggested that 3st3-HS might be a tool to specifically increase FGFR2b-
dependent proliferation and expand KIT+ progenitors.
3st3-HS increases endogenous 3-O-sulfated HS and increases FGF10/FGFR2b binding to
the epithelium
We next confirmed that treatment with 3st3-HS also increased the endogenous 3-O-sulfated
HS on the epithelium by staining with gD1. An increase in gD1 binding was detected on
epithelium treated with 3st3-HS compared to control HS (Figure 6A). In addition, a Ligand
and Carbohydrate Engagement (LACE) assay was performed with recombinant FGF10 and
FGFR2b-Fc to determine whether the increase in endogenous gD1-binding HS also resulted
in increased binding of the FGF10/FGFR2b complex, which was detected with anti-human-
Fc antibodies. Indeed, an increase in FGF10/FGFR2b assembly was detected on epithelia
treated with 3st3-HS compared to HS (Figure 6B). These data are consistent with the
hypothesis that an increase in endogenous 3-O-sulfated HS increases FGF10/FGFR2b
signaling.
3st3-HS specifically expands fetal and adult epithelial KIT+FGFR2b+ progenitors
Since combined KIT/FGFR2b signaling increases the expansion of KIT+FGFR2b+K14+
epithelial endbud progenitors (Lombaert et al., 2013), we predicted that exogenous 3st3-HS
would specifically enhance their expansion. We immunostained epithelia treated with 3st3-
HS or HS for KIT, CCND1, Ki67, K14, and K19 (Figure 6C). 3st3-HS-treatment increased
staining compared to HS, for KIT, K14 and the proliferative markers CCND1 and Ki67
(Figure 6C top and middle panels). 3st3-HS did not affect staining of K19, a marker of
ductal cells (Figure 6C middle panels). We further confirmed that 3st3-HS-treated epithelial
KIT+ progenitors expressed FGFR2b (Figure 6C, lower panels). A profile plot shows that
both KIT and FGFR2b localize near the membrane at a calculated overlap coefficient of
r=0.54 ± 0.015.
Since KIT+FGFR2b+ progenitors are present in the adult SMG, we asked whether 3-O-HS
expanded them in vitro, which is an important step to obtain more progenitors for
transplantation. Thus, we used in vitro spheroid culture of adult SMG progenitors, termed
salispheres, as previously used to enrich for KIT+ progenitors for autologous transplantation
to regenerate irradiation-damaged salivary glands (Lombaert et al., 2008). The addition of
3st3-HS and FGF10 increased the number and size of salispheres by day 3, an indicator of
increased progenitor numbers, compared to HS treated, (Figure 6D). Remarkably, even at 6
days of culture, the salispheres contained cells expressing KIT that were actively
Patel et al. Page 7






















proliferating (CCND1+) (Figure 6D). Together, these data indicate that exogenous 3st3-HS
expands and prolongs the proliferation of adult KIT+FGFR2b+ progenitors.
DISCUSSION
Here we propose a model where 3-O-HS stabilizes FGF10/FGFR2b complex formation to
increase FGFR2b-dependent MAPK signaling, gene expression and proliferation (Figure 7).
The proliferative response of KIT+FGFR2b+ progenitors is enhanced and maintained via
rapid feedback to increase Hs3st expression. Thus, 3-O-HS provides a cellular mechanism to
respond to a specific growth factor and amplify that response to expand specific progenitors.
The function of specific HS modifications fine-tuning growth factor signaling via regulation
of HS biosynthetic enzymes is an emerging paradigm supported by other studies. For
example, a 6-O-endosulfatase fine-tunes Hedgehog (Hh) patterning activity of the
Drosophila wing disc and this involves regulation of the sulfatase expression pattern by
EGFR signaling (Wojcinski et al., 2011). In addition, during lacrimal gland development N-
sulfation potentiates FGF10/FGFR2 interactions and Shp2/Erk signaling, which feedback to
regulate Ndst expression (Pan et al., 2008).
The 3-O-sulfotransferase family creates the least abundant type of sulfate modification,
making it difficult to isolate and analyze these rare 3-O-sulfated products. Currently, there is
a lack of 3-O-sulfated standards for biochemical analysis, and only recently the enzyme that
specifically removes 3-O-sulfation, arylsulfatase G, was identified (Kowalewski et al.,
2012). Research has focused on Hs3st1 because it forms the AT-binding HS epitope, but
here we used a bioengineered 3-O-HS to investigate Hs3st3 function. Treatment of kidney
HS, which has low endogenous 3-O-sulfation, with recombinant 3-O-sulfotransferases
enzymes added ~2 extra sulfates/HS chain and allowed us to probe specific functions of
3st3-HS. While HS modified by both Hs3st1 and Hs3st3 have some similar functions, the
specific epitopes on these HS chains responsible for specific activity in a particular assay
remain to be defined, and epitopes may have some overlapping functions in specific assays,
or multiple epitopes may influence a particular function. Our data support the hypothesis
that the sulfate pattern, and not just overall charge, is critical for specific HS functions and
fine-tuning of growth factor signaling.
The rapid response to 3-O-HS in KIT+FGFR2b+ progenitors may be due to a number of
factors. Firstly, we show that 3-O-HS binds FGFR2b, which stabilizes the FGF10/FGFR2b
complex, and this may affect the FGF binding affinity. The binding affinity of FGF10 to HS
and FGFR2b are crucial for its biological outcome. A mutation in the HS binding site of
FGF10, reduces its binding to HS converting FGF10 into a functional mimic of FGF7, in
terms of organ morphogenesis and global gene expression. Whereas, a mutation in FGF10
binding site for FGFR2b, reduces the overall growth response (Makarenkova et al., 2009).
Secondly, the binding of FGF10 to FGFR2b increases endocytic recycling of FGFR2b,
which correlates with higher mitogenic activity, whereas the binding of FGF7 results in
receptor ubiquitination and degradation (Belleudi et al., 2007). We speculate that formation
of 3-O-HS/FGF10/FGFR2b complexes combined with endocytic FGFR recycling, would
increase and maintain a mitotic response in KIT+FGFR2b+ progenitors.
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We propose that a similar mechanism involving 3-O-HS may exist in other organs that
develop via FGFR2b-dependent branching morphogenesis such as the lung, kidney,
mammary gland, pancreas, lacrimal gland and prostate gland (Davies, 2002; Hogan and
Kolodziej, 2002; Tsau et al., 2011). Since multiple Hs3sts are expressed in a variety of
tissues (Figure S1D), some redundancy or overlap in their function may exist. However, for
the lung, we show that 3-O-HS has similar effects on epithelial endbuds (Figure S3), which
also express KIT+FGFR2b+ progenitors (Lombaert et al., 2013). Lacrimal gland endbud
proliferation is dependent on FGF10 and NDST1 (Pan et al., 2008). However, NDST1 acts
early in HS biosynthesis, and the effects of reducing N-sulfation on 3-O-sulfation were not
examined. Thus, unique HS-modifications may alter tissue-specific progenitor expansion.
Since Hs3sts modulate growth factor responses, it is not surprising that they influence tumor
progression (Bishop et al., 2007). Extensive DNA methylated sites are present in HS3ST1,
HS3ST3A1 and HS3ST6 in HEMC chondrosarcoma cells that repress HS3ST expression and
enhance the invasive phenotype (Bui et al., 2010). Hypermethylation of Hs3st2 also reduces
it's expression and occurs in a wide range of human cancers including breast, colon, lung,
and pancreatic cancers (Miyamoto et al., 2003). Thus, tumorogeneisis correlates with
reduced HS3ST-enzymes, which may disrupt the specificity and fine-tuning of growth factor
responses. It will be interesting to determine whether 3-O-HS can modify growth factor
responses of cancer cells.
Apart from expanding progenitors, HS sulfation also influences progenitor fate (Cool and
Nurcombe, 2006). Studies of mouse embryonic stem cells (ESCs) with HS biosynthetic
enzymes deleted, show there are effects on pluripotency and FGF and BMP-dependent
differentiation (Kraushaar et al., 2012; Lanner et al., 2010). Yet, in vitro addition of HS
saccharides of specific length and sulfation directed BMP-dependent ESC differentiation
and FGF-dependent neuronal cell differentiation (Holley et al., 2011; Pickford et al., 2011).
Additionally, an embryonic form of HS, whose HS structure was not identified, enhanced
the multipotency of human mesenchymal stem cells (Helledie et al., 2012). Our data shows
that 3-O-HS can expand both fetal and adult KIT+FGFR2b+ progenitors in vitro, but it is
unclear whether it influences their cell fate or potency. Other HS-dependent growth factor
pathways may be involved. Additionally, heparanases or sheddases, which can release 3-O-
HS from the KIT+ progenitor surface, may also influence the fate of adjacent progenitors.
An important question remains as to the identity of core proteins that have 3-O-HS added to
them. Our FACS data show increased, but not significant, expression of syndecan 4 (Sdc4)
in KIT+ progenitors (Figure S1A). Our temporal expression data, however, shows that Hs3st
gene expression increases within 1–2 hr, but that the increase in core protein expression
occurs later, after 6 hr (data not shown). This suggests the cell could first increase enzyme
synthesis to modify the pool of HS being synthesized, but then also upregulate specific core
proteins later. Indeed, 3-O-HS production is regulated by limiting levels of HS3ST enzymes
that modify only a portion of an excess precursor pool (Shworak et al., 1996; Yabe et al.,
2001). Moreover within a clonal cell line, HS structure appears to be equivalent across
multiple core proteins (Shworak et al., 1994). It is unclear whether syndecan 4 HS is
specifically 3-O-sulfated in response to FGF10, and the dynamics of HSPG core synthesis
and coordination with changes in the HS biosynthetic program require further investigation.
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In conclusion, we show that the fine-tuning of HS biosynthesis at its terminal step, by
adding the least abundant sulfate group, ensures a rapid and specific response to FGF10
signals. Autocrine feedback, from 3-O-HS/FGF10/FGFR2b signaling, upregulates Hs3st3
expression, to increase 3-O-HS and maintain the proliferation of epithelial KIT+FGFR2b+
progenitors. We propose that 3-O-HS may increase the expansion of KIT+FGFR2b+
progenitors from patient biopsies in vitro for use in autologous progenitor transplantation to
regenerate organs.
EXPERIMENTAL PROCEDURES
Ex Vivo Organ Culture and Fluorescence-activated cell sorting
Fetal SMG or lung organ cultures and FACS analysis were recently described in (Lombaert
et al., 2013). Single cell suspensions of SMGS were incubated with anti-KIT-APC (BD
Pharmingen) and anti-ECAD-PE (R&D), and sorted on a BD Aria II.
Labeling of HS
AT-488 was prepared as previously described (Girardin et al., 2005). We used HSV-1gD,
which has a truncated ectodomain at residues 285 and binds to receptors in vitro with a 100-
fold increased affinity than full-length ectodomains (Krummenacher et al., 1999). For
details, see Extended Experimental Procedures.
Preparation of 3-OST-modified HS
The 3-OST-modified HS was prepared by incubating HS (from bovine kidney) and purified
3-OST-1 and 3-OST-3 enzymes as described (Xu et al., 2008). Briefly, 10 µg HS, 100 mM
PAPS, 50 mM MES, pH 7.0, 10 mM MnCl2, 5 mM MgCl2, and 1% Triton X-100(v/v) and 4
mg of 3-OST-1 or 3-OST-3 proteins were incubated in 100 µl at 37°C for 1 hr. The 3-OST-
modified HS was isolated by a DEAE-Sephacel chromatography. To monitor the extent of
3-O-sulfation, 3-O-[35S] sulfated HS was prepared using [35S] PAPS (specific activity 6500
cpm/nmole, 100 mM). Disaccharide analysis of the modified HS and binding to AT and gD1
were described (Xu et al 2008). Typically, ~two 3-O-sulfo groups per polysaccharide were
incorporated.
Quantitative PCR (qPCR)
Real time PCR was performed as previously described (Patel et al., 2008). Briefly, cDNA
was generated from DNase-free RNA, amplified and gene expression normalized to the
housekeeping gene, Rps29. The reactions were run in triplicate, and the experiment repeated
three times.
In Situ Hybridization
DIG-labeled RNA probes were prepared using the appropriate RNA polymerase using the
DIG RNA labeling Kit (Roche Applied Science) according to the manufacturer's
instructions. In situ hybridization was previously described (Patel et al., 2008).
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Equal molar concentrations (5 nM) of recombinant FGF10, recombinant FGFR2b and HS
were incubated together for pull-down assays as described (Sugaya et al., 2008) with slight
modification. For details, see Extended Experimental Procedures.
FGFR2b and FGF10/GAG binding assay
An enzyme-based assay was performed to determine the binding of FGFR2b or FGF10 to 3-
O-HS using 96-well Heparin/GAG binding plates (Iduron Ltd), according to the
manufacturer’s protocol. FGFR2b and FGF10 binding detected as described in the Extended
Experimental Procedures.
RNA interference and heparan sulfate rescue
At least two siRNAs targeting each Hs3st gene were purchased (Qiagen or Dharmacon). The
siRNA sequences used were: TCA ACC GCA AGT TCT ACC AGA to target Hs3st3a1,
Hs3st3b1 and Hs3st6, referred as Hs3st3a-3b-6 (Dharmacon), CAC CTC CTT GTC AAA
TCT ATA to target Hs3st1 and AAT TCT CCG AAC GTG TCA CGT the non-silencing
control (both Qiagen). Isolated epithelial rudiments cultured in laminin-111 gel were
transfected with a combination of Hs3st1 and Hs3st3a-3b-6 (100 nM each) siRNA in 200 µl
of culture medium using oligofectamine (Invitrogen) as previously described (Rebustini et
al., 2007). HS or 3-O-HS (0.5 µg/ml or 35 nM) was added following 16 hr of siRNA
transfection. Gene knockdown was measured by qPCR analysis after 40 hr culture.
Immunofluorescence analysis and detection of cell proliferation
Whole mount immunofluorescence was performed as previously described (Rebustini et al.,
2012). SMG epithelial proliferation was detected using Click-iT EdU Alexa Fluor 488
proliferation Kit (Invitrogen) according to the manufacturer’s protocols. Binding of labeled
AT488 or gD1 was performed as described in the Extended Experimental Procedures.
Images were obtained using a Zeiss LSM 710 confocal microscope.
BaF3 Proliferation assays
BaF3 cell stably expressing the FGFR splice isoforms (FGFR1b, 2b, 2c and 3c) were kindly
provided by Dr. David Ornitz (Washington University) and maintained as previously
described (Ornitz et al., 1996). For a detailed protocol, see Extended Experimental
Procedures.
Salisphere assay
This assay was performed as previously described (Lombaert et al., 2008) with minor
modification to the culture medium. Carbachol (10 nM), Y-27632 rock inhibitor (5 µM)
(Calbiochem), FGF10 (50 ng/mL) with or without HS or 3st3-HS (50 ng/mL/3.6 nM) was
also supplemented to the culture medium. At day 3, the salispheres were counted and
photographed to measure their size. The salispheres were cultured for six days and the either
lysed for RNA extraction or stained for KIT and CCND1.
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Data were log transformed before all statistical analysis. We used GraphPad Prism 6
software (GraphPad Software). The Student’s t test was used to compare two different
groups, one-way ANOVA with post hoc Dunnett’s test to compare more than two
experimental groups, and multiple unpaired t tests were analyzed by a False Discovery Rate
approach where Q, the acceptable rate for false discoveries was set to 5%. Graphs show the
mean ± SEM for each group from three or more experiments.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• Epithelial KIT+ progenitors express enzymes that generate 3-O-sulfated HS
• 3-O-sulfotransferases are rapidly upregulated by FGF10/FGFR2b signaling
• 3-O-sulfated HS binds FGFR2b and amplifies FGF10/FGFR2b signaling and
proliferation
• 3-O-sulfated HS expands fetal and adult KIT+FGFR2b+ progenitors
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Figure 1. KIT+ epithelial endbud progenitors are enriched for HS 3-O-sulfotransferase
expression and 3-O-HS is localized in the epithelial endbuds
(A) qPCR analysis of isolated E13 SMG epithelia and mesenchyme. Gene expression was
normalized to Rps29.
(B) The expression levels of HS biosynthetic enzymes were compared by qPCR in cDNA
from the KIT+ versus KIT− ECAD+ FACS sorted cells. Gene expression was normalized to
expression in the KIT− cells and Rps29. A false discovery rate (Q) for multiple unpaired t-
tests was set to 5%. *p ≤ 0.05 **p ≤ 0.01 and ***p ≤ 0.001. Error bars: SEM. Images are
single confocal projection with KIT (red) and Perlecan (pink) labeling in an E13 SMG.
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Scale bar; 200 µm. FACS plot shows KIT+ ECAD+ cells (red box) and KIT− ECAD+ cells
(green box) sorted from E13 SMGs.
(C) Sections of whole-mount in situ analysis of E13 SMG confirm the localization of Hs3st
isoforms in the endbud (dotted line); counterstained with nuclear fast red.
(D) Staining of E13 SMGs with labeled antithrombin (AT488, green). Heparitinase (HPT)
but not chondroitinase (CHABC) treatment for 2 hr abolished AT488 labeling. Perlecan
(blue) localized in the basement membrane and ECAD (red) labeled the epithelium. Images
are single confocal sections, scale bar: 20 µm.
(E) Staining with HSV-1 gD285 protein localized Hs3st3-type 3-O-HS at the epithelial cell
surface. Heparitinase treatment also decreased binding of HSV-1 gD (green). Perlecan (blue)
and TGFBR3 (red), which stains the epithelium, are shown. Images are single confocal
sections, scale bar: 5 µm.
See also Figure S1.
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Figure 2. Hs3st expression is rapidly regulated by FGFR2b-dependent MAPK signaling and is
reduced when KIT signaling is reduced
(A) Isolated E13 epithelia (insert image) were treated with 400 ng/ml FGF10 for 1, 2 or 4 hr,
which does not affect morphogenesis. Gene expression was normalized to epithelium at 0 hr
and Rps29.
(B) SMGs (E13) were treated for 4 hr with an FGFR inhibitor (SU5402, 5µM), recombinant
FGFR2b (25nM), a MAPK inhibitor (UO126, 20µM), a PI3-K inhibitor (LY294002, 25µM)
and a SCF/KIT inhibitor (ISCK03, 20µM). qPCR analysis was normalized to DMSO or
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rFGFR1b (a control for rFGFR2b). No morphological changes were observed between
treatments after 4 hr (insert image).
(C) Inhibition of KIT signaling in SMGs with a KIT inhibitor (ISCK03, 20µM) or in vivo
using E14 KitW/W mice reduced SMG branching morphogenesis compared to controls. The
bud count was normalized (%) to control. Scale bar; 200 µm.
(D) SMGs (E13) either treated with a KIT inhibitor (ISCK03, 20µM) for 24 hr or isolated
from E13 KitW/W mice have reduced expression of Hs3st3a1 and Hs3st3b1. Gene expression
was normalized to DMSO-carrier control or wild-type control and Rps29.
Error bars: SEM. ANOVA (A–C); Student t-test (D); * p < 0.05, ** p < 0.01 and *** p <
0.001.
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Figure 3. 3st3-HS preferentially binds FGFR2b to increase ternary complex formation of
FGF10/FGFR2b, and proliferation of FGFR2b-expressing BaF3 cells
(A–B) Binding of FGFR2b and FGFR1b (A) or FGF10 (B) to immobilized GAGS.
FGFR2b, but not FGF10, specifically binds to immobilized 3st3-HS. ELISA assays were
performed in triplicate and repeated at least three times. Error bars: SEM.
(C) 3-O-HS increases the amount of FGF10 immunoprecipitated with FGFR2b. The
intensity of the protein bands was normalized to FGFR2b and shown as a fold change in
ratio of FGF10/FGFR2b. The graphs are 3 experiments combined and the blots from a
representative experiment.
(D) BaF3 cells expressing FGFR2b or FGFR1b were incubated with 25nM GAGS (CSA,
heparin, HS, 3st1-HS, or 3st3-HS) and 50nM FGF10 or 5nM FGF1. After 40 hr, the relative
cell proliferation (A490) was determined. Data were normalized to FGFR2b-BaF3 cells
treated with FGF10 or FGF1 and heparin.
Error bars: SEM. ANOVA; * p < 0.05, ** p < 0.01 and *** p < 0.001.
See also Figure S2.
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Figure 4. 3-O-sulfated-HS increases FGF10-dependent epithelial morphogenesis by increasing
proliferation and FGFR2b-downstream gene expression
(A) FGF10 cultured E13 SMG epithelia treated with HS, 3st1-HS or 3st3-HS for 28 hr. 3st3-
HS increased endbud morphogenesis of FGF10-treated epithelium compared to HS
(control). Morphogenic index (endbud number × width × duct length, in AU) increases with
addition of 3-O-HS. Scale bar; 50 µm.
(B) Single confocal sections showing cell proliferation (red) in epithelia cultured for 28 hr.
Quantification of fluorescence intensity normalized to total nuclei staining and expressed as
a ratio to the HS treated epithelia. At least five epithelia/condition were used for
quantification from three independent experiments. Scale bar; 10 µm.
(C) 3st3-HS increased MAPK signaling within 1 hr and both 3st-HS maintained it at 24 hr in
FGF10-cultured epithelia. Band intensity of pMAPK was normalized to total MAPK and
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expressed as a fold change in ratio compared to HS. The graphs are 3 experiments combined
and the blots from a representative experiment.
(D) Gene expression was measured by qPCR and normalized to epithelia cultured for 28 hr
with HS and Rps29.
Error bars: SEM. ANOVA; *p < 0.05; **p < 0.01, and ***p < 0.001.
See also Figure S3.
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Figure 5. Knockdown of Hs3sts decreases epithelial morphogenesis and Hs3st expression, which
are both rescued by exogenous 3st3-HS
(A) Light micrographs of FGF10-cultured E12 SMG epithelia were treated for 40 hr with
non-silencing (NS) or Hs3st siRNA. Scale bar; 50 µm.
(B) Quantification of epithelial morphogenesis after 40 hr of siRNA transfection.
Knockdown of the Hs3sts inhibited branching compared to NS-siRNA. Error bars SEM.
ANOVA; ***p<0.001, compared to control.
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(C) Knockdown of Hs3sts decreased expression of Etv4, Etv5, Ccnd1, Myc, Kit and Kitl.
Gene expression was measured by qPCR and normalized to NS-siRNA (dotted line). Error
bars: SEM. Student’s t-test *p < 0.05; **p < 0.01, and ***p < 0.001.
(D) Light micrographs of FGF10-cultured E12 SMG epithelia were treated with NS or Hs3st
siRNA. Exogenous HS, 3st1-HS, or 3st3-HS was added to these cultures following 16 hr of
siRNA-treatment. Scale bar; 50 µm.
(E) Quantification of epithelial morphogenesis after 40 hr of siRNA transfection. Error bars:
SEM. ANOVA; ***p<0.001, compared to epithelia treated with NS and HS.
(F) Gene expression of Hs3st1, Hs3st3a1 and Hs3st3b1 is partially restored by 3st1-HS and
3st3-HS. Gene expression was measured by qPCR and normalized to NS-siRNA (dotted
line). Error bars: SEM.
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Figure 6. 3-O-sulfated-HS increases endogenous 3-O-HS, FGF10/FGFR2b-Fc binding,
proliferation and KIT expression
(A–C) FGF10 cultured E13 SMG epithelia treated with HS or 3st3-HS for 28 hr were
stained. (A) gD1 staining (green) or (B) with FGF10/FGFR2b-Fc (LACE assay, green) and
ECAD (red). (C) CCND1, KIT (green) and DAPI (blue) top panels, K14 (red), K19 (green),
Ki67 (blue) middle panels, and FGFR2 (red), KIT (green) and DAPI (blue) lower panels.
The profile plots (lower right) quantify the relative intensity of the KIT and FGFR2 protein
distribution at the position along the white dotted line in the overlay image. The
fluorescence signal from anti-KIT-Cy2 colocalized with anti-FGFR2-Cy3
immunofluorescence signal with an overlap coefficient of r=0.54 ± 0.015. Images are 2 µm
confocal sections. Scale bars: 10 µm and 2 µm in lower right panel. Quantification of
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fluorescence intensity normalized to total nuclei staining and expressed fold increase
compared to HS treated epithelia. At least five epithelia from three independent experiments
were used for quantification.
(D) 3-O-HS treatment increases salisphere size (upper panel). Quantification of the number
and diameter of salispheres formed after 3 days. 3-O-HS increases both the count and size of
salispheres compared to HS. Confocal sections of salispheres cultured for 6 days with HS or
3st3-HS stained with KIT (green, middle panel) and CCND1 (green, lower panel).
Quantification of KIT and CCND1 fluorescence intensity normalized to total nuclei staining
and expressed as a fold increase compared to HS treated salispheres. At least five salispheres
from each of three independent experiments were used for quantification. Scale bar; 10 µm.
Error bars: SEM. Student’s t-test; *p < 0.05, **p < 0.01, and ***p < 0.001.
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Rapidly altering 3-O-sulfation provides a cellular mechanism to modulate the response to
FGFR2b signaling and control progenitor expansion. Model showing that 3-O-HS rapidly
increases 3-O-sulfotranseferase expression, 3-O-sulfated HS on the epithelium and FGF10/
FGFR2b complex formation, MAPK signaling, gene expression of FGFR2b signaling
targets, proliferation genes, and Kit and its ligand, which expands the KIT+FGFR2b+
progenitors.
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